Abstract
The recent wide spreading of the H5N1 avian influenza virus (AIV) in Asia, Europe and Africa and its ability to cause fatal infections in human has raised serious concerns about a pending global flu pandemic. Neuraminidase (NA) inhibitors are currently the only option for treatment or prophylaxis in humans infected with this strain. However, drugs currently on the market often meet with rapidly emerging resistant mutants and only have limited application as inadequate supply of synthetic material. To dig out helpful information for designing potent inhibitors with novel structures against the NA, we used automated docking, CoMFA, CoMSIA, and HQSAR methods to investigate the quantitative structure–activity relationship for 126 NA inhibitors (NIs) with great structural diversities and wide range of bioactivities against influenza A virus. Based on the binding conformations discovered via molecular docking into the crystal structure of NA, CoMFA and CoMSIA models were successfully built with the cross-validated q 2 of 0.813 and 0.771, respectively. HQSAR was also carried out as a complementary study in that HQSAR technique does not require 3D information of these compounds and could provide a detailed molecular fragment contribution to the inhibitory activity. These models also show clearly how steric, electrostatic, hydrophobicity, and individual fragments affect the potency of NA inhibitors. In addition, CoMFA and CoMSIA field distributions are found to be in well agreement with the structural characteristics of the corresponding binding sites. Therefore, the final 3D-QSAR models and the information of the inhibitor–enzyme interaction should be useful in developing novel potent NA inhibitors.
Similar content being viewed by others
References
de Jong MD, Hien TT (2006) J Clin Virol 35:2
Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS (2005) Nature 437:209
Laver G (2005) Nature 434:821
Gani R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S (2005) Emerg Infect Dis. Available from http://www.cdc.gov/ncidod/EID/vol11no09/04-1344.htm
Colman PM (1994) Protein Sci 3:1687
Young D, Fowler C, Bush K (2001) Philos Trans R Soc Lond B Biol Sci 356:1905
Lew W, Chen X, Kim CU (2000) Curr Med Chem 7:663
Kim CU, Chen X, Mendel DB (1999) Antivir Chem Chemother 10:141
von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Oliver SW, et al (1993) Nature 363:418
Kim CU, Lew W, Williams MA, Liu H, Zhang L, Swaminathan S, Bischofberger N, Chen MS, Mendel DB, Tai CY, Laver WG, Stevens RC (1997) J Am Chem Soc 119:681
Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y (2005) Nature 437:1108
Maring CJ, Stoll VS, Zhao C, Sun M, Krueger AC, Stewart KD, Madigan DL, Kati WM, Xu Y, Carrick RJ, Montgomery DA, Kempf-Grote A, Marsh KC, Molla A, Steffy KR, Sham HL, Laver WG, Gu YG, Kempf DJ, Kohlbrenner WE (2005) J Med Chem 48:3980
Stoll V, Stewart KD, Maring CJ, Muchmore S, Giranda V, Gu YG, Wang G, Chen Y, Sun M, Zhao C, Kennedy AL, Madigan DL, Xu Y, Saldivar A, Kati W, Laver G, Sowin T, Sham HL, Greer J, Kempf D (2003) Biochemistry 42:718
Chand P, Bantia S, Kotian PL, El-Kattan Y, Lin TH, Babu YS (2005) Bioorg Med Chem 13:4071
Verma RP, Hansch C (2006) Bioorg Med Chem 14:982
Yi X, Guo Z, Chu FM (2003) Bioorg Med Chem 11:1465
Klebe G, Abraham U, Mietzner T (1994) J Med Chem 37:4130
Doucette KE, Aoki FY (2001) Expert Opin Pharmacother 2:1671
Chand P, Babu YS, Bantia S, Rowland S, Dehghani A, Kotian PL, Hutchison TL, Ali S, Brouillette W, El-Kattan Y, Lin TH (2004) J Med Chem 47:1919
Cramer RD, David EP, Jeffrey DB (1988) J Am Chem Soc 110:5959
Tong W, Lowis DR, Perkins R, Chen Y, Welsh WJ, Goddette DW, Heritage TW, Sheehan DM (1998) J Chem Inf Comput Sci 38:669
Atigadda VR, Brouillette WJ, Duarte F, Ali SM, Babu YS, Bantia S, Chand P, Chu N, Montgomery JA, Walsh DA, Sudbeck EA, Finley J, Luo M, Air GM, Laver GW (1999) J Med Chem 42:2332
Kim CU, Lew W, Williams MA, Wu H, Zhang L, Chen X, Escarpe PA, Mendel DB, Laver WG, Stevens RC (1998) J Med Chem 41:2451
Lew W, Wu H, Mendel DB, Escarpe PA, Chen X, Laver WG, Graves BJ, Kim CU (1998) Bioorg Med Chem Lett 8:3321
Williams MA, Lew W, Mendel DB, Tai CY, Escarpe PA, Laver WG, Stevens RC, Kim CU (1997) Bioorganic Med Chem Lett 7:1837
Wang GT, Chen Y, Wang S, Gentles R, Sowin T, Kati W, Muchmore S, Giranda V, Stewart K, Sham H, Kempf D, Laver WG (2001) J Med Chem 44:1192
Cheng Y, Prusoff WH (1973) Biochem Pharmacol 22:3099
Smith PW, Sollis SL, Howes PD, Cherry PC, Starkey ID, Cobley KN, Weston H, Scicinski J, Merritt A, Whittington A, Wyatt P, Taylor N, Green D, Bethell R, Madar S, Fenton RJ, Morley PJ, Pateman T, Beresford A (1998) J Med Chem 41:787
Varghese JN, Smith PW, Sollis SL, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL, Colman PM (1998) Structure 6:735
Weiner SJ, Kollman PA, Case DA, Singh C, Ghio G, Alagona S, Profeta P, Weiner P (1984) J Am Chem Soc 106:765
SYBYL (2000) Version68; Tripos Associates; St Louis, MO
Clark M, Cramer R, Vannodenbosch N (1989) Validation of the general-purpose tripos 5.2 force-field. J Comput Chem 10:982
Gasteiger J, Marsili M (1981) Org Magn Reson 15:353
Marsili M, Gasteiger J (1980) Croat Chem Acta 53:601
Gasteiger J, Marsili M (1980) Tetrahedron 36:3219
Dewar MJS, Zoebisch EG, Healy EF, Stewart JJP (1985) J Am Chem Soc 107:3902
Morris GM, Goodsell DS, Huey R, Hart WE, Halliday S, Belew R, Olson AJ (1999) AUTODOCK Version 3.0.3. The Scripps Research Institute, Molecular Graphics Laboratory, Department of Molecular Biology
Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) J Comput Chem 19:1639
Solis FJ, Wets RJ-B (1981) Math Operat Res 6:19
Weiner SJ, Kollman PA, Nguyen DT, Case DA (1986) J Comput Chem 7:230
Mehler EL, Solmajer T (1991) Protein Eng 4:903
Bush BL, Nachbar RB Jr (1993) J Comput Aided Mol Des 7:587
Viswanadhan VN, Ghose AK, Revankar GR, Robins RK (1989) J Chem Inf Comput Sci 29:163
Ghose AK, Crippen GM (1986) J Comput Chem 7:565
Tong W, Lowis DR, Perkins R, Chen Y, Welsh WJ, Goddette DW, Heritage TW, Sheehan DM (1998) J Chem Inf Model 38:669
Babu YS, Chand P, Bantia S, Kotian P, Dehghani A, El-Kattan Y, Lin TH, Hutchison TL, Elliott AJ, Parker CD, Ananth SL, Horn LL, Laver GW, Montgomery JA (2000) J Med Chem 43:3482
Finley JB, Atigadda VR, Duarte F, Zhao JJ, Brouillette WJ, Air GM, Luo M (1999) J Mol Biol 293:1107
Varghese JN, Epa VC, Colman PM (1995) Protein Sci 4:1081
Smith BJ, McKimm-Breshkin JL, McDonald M, Fernley RT, Varghese JN, Colman PM (2002) Structural studies of the resistance of influenza virus neuramindase to inhibitors, vol 45, pp 2207–2212
Tropsha A, Gramatica P, Gombar VK (2003) Quant Struct-act Relatsh 22:1
Wold S, Eriksson L (1995) In: van de Waterbeemd H (ed) Chemometrics methods in molecular design. VCH, Weinheim, pp 309–318
Acknowledgements
We thank Professor Arthur J. Olson for his kindness in offering us the AUTODOCK 3.0.3 program. We gratefully acknowledge financial support from National Natural Science Foundation of China (Grants 20102007, 29725203, and 20072042), the State Key Program of Basic Research of China (Grant 2004CB518901), and Shanghai Science and Technology Commission (03DZ19228, 05JC14092 and 05QMX1464).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zheng, M., Yu, K., Liu, H. et al. QSAR analyses on avian influenza virus neuraminidase inhibitors using CoMFA, CoMSIA, and HQSAR. J Comput Aided Mol Des 20, 549–566 (2006). https://doi.org/10.1007/s10822-006-9080-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10822-006-9080-0